Linked Life Data

18292544

Source:http://linkedlifedata.com/resource/pubmed/id/18292544

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2008-2-22
pubmed:abstractText
Improvement of the strategy to target tumor Ags to dendritic cells (DCs) for immunotherapy requires the identification of the most appropriate ligand/receptor pairing. We screened a library of Ab fragments on mouse DCs to isolate new potential Abs capable of inducing protective immune responses. The screening identified a high-affinity Ab against CD36, a multi-ligand scavenger receptor primarily expressed by the CD8alpha+ subset of conventional DCs. The Ab variable regions were genetically linked to the model Ag OVA and tested in Ag presentation assays in vitro and in vivo. Anti-CD36-OVA was capable of delivering exogenous Ags to the MHC class I and MHC class II processing pathways. In vivo, immunization with anti-CD36-OVA induced robust activation of naive CD4+ and CD8+ Ag-specific T lymphocytes and the differentiation of primed CD8+ T cells into long-term effector CTLs. Vaccination with anti-CD36-OVA elicited humoral and cell-mediated protection from the growth of an Ag-specific tumor. Notably, the relative efficacy of targeting CD11c/CD8alpha+ via CD36 or DEC205 was qualitatively different. Anti-DEC205-OVA was more efficient than anti-CD36-OVA in inducing early events of naive CD8+ T cell activation. In contrast, long-term persistence of effector CTLs was stronger following immunization with anti-CD36-OVA and did not require the addition of exogenous maturation stimuli. The results identify CD36 as a novel potential target for immunotherapy and indicate that the outcome of the immune responses vary by targeting different receptors on CD8alpha+ DCs.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0022-1767
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
180
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
3201-9
pubmed:meshHeading
pubmed-meshheading:18292544-Animals, pubmed-meshheading:18292544-Antibodies, Monoclonal, pubmed-meshheading:18292544-Antigen Presentation, pubmed-meshheading:18292544-Antigens, CD36, pubmed-meshheading:18292544-Antigens, CD8, pubmed-meshheading:18292544-Cell Differentiation, pubmed-meshheading:18292544-Cross-Priming, pubmed-meshheading:18292544-Dendritic Cells, pubmed-meshheading:18292544-Endocytosis, pubmed-meshheading:18292544-Female, pubmed-meshheading:18292544-Histocompatibility Antigens Class I, pubmed-meshheading:18292544-Histocompatibility Antigens Class II, pubmed-meshheading:18292544-Immunoglobulin Fab Fragments, pubmed-meshheading:18292544-Mice, pubmed-meshheading:18292544-Mice, Inbred C57BL, pubmed-meshheading:18292544-Mice, Transgenic, pubmed-meshheading:18292544-Ovalbumin, pubmed-meshheading:18292544-Peptide Library, pubmed-meshheading:18292544-Recombinant Fusion Proteins, pubmed-meshheading:18292544-Signal Transduction
pubmed:year
2008
pubmed:articleTitle
Selection of an antibody library identifies a pathway to induce immunity by targeting CD36 on steady-state CD8 alpha+ dendritic cells.
pubmed:affiliation
International Centre for Genetic Engineering and Biotechnology, Trieste, Italy.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't